The movement occurred after a pharmaceutical company admitted in court an adverse effect, considered very rare. The syndrome is characterized by the combination of blood clot formation and low levels of platelets in the blood. The company, however, contests the cases in the process, arguing that STT has other more probable causes.
There are 51 cases of deaths or serious injuries reported by families to the courts. These people would have been victims of TTS (Thrombosis Syndrome with Thrombocytopenia). The families are asking, in a collective action, for compensation that could reach up to 100 million pounds (around R$646 million).
In a note to UOL, AstraZeneca states that the adverse effect has been known since April 2021 with an update from the UK regulatory agency. “Our sympathies go out to anyone who has lost loved ones or reported health problems. Patient safety is our highest priority and regulatory authorities have clear and rigorous standards to ensure the safe use of all medicines, including vaccines.”
The recommendation for the vaccine produced by AstraZeneca in Brazil was updated in December 2022. The Ministry of Health began recommending the vaccine for people aged 40 and over, as the adverse effect was identified in the previous age group.
The first class action case was reportedly filed last year by Jamie Scott, according to The Telegraph. The father of two was left with permanent brain damage after developing a blood clot and a hemorrhage in the brain that prevented him from working after receiving the vaccine in April 2021.
Tags: AstraZeneca withdraws covid vaccine admitting rare adverse effect
